UF’s Mei He is part of a team working to support a new extracellular vesicle platform used to develop gene therapy. EVs are small, membrane-bound vesicles that act as envelopes delivering intercellular communications that influence a cell’s behavior or function. By optimizing their EV platform, He hopes to accelerate clinical translation of EV-based therapeutic products.
“With this support, our team will be able to develop a scalable manufacturing pipeline and establish quality control criteria for EV-based genome editing products,” says He. “The outcome will have a significant impact on accelerating the translation of novel, safe and effective therapeutics and genome editing strategies into first-in-human clinical trials.”
View Related Expert Profiles: Go to Source
